STAA - Eye Lens Maker STAAR Surgical Expects Q1 Sales To Beat Consensus | Benzinga
Thursday, STAAR Surgical Company (NASDAQ:STAA) reported preliminary net sales for the first quarter of 2024 of more than $77 million versus the consensus of $72.13 million, with U.S. ICL sales expected to be $5 million for the quarter.
This represents the company’s highest quarterly ICL sales in the U.S. since the company obtained U.S. FDA approval for the EVO ICL in March 2022.
“STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results, including a record quarter in the U.S.,” said Tom Frinzi, President and CEO.
“U.S. ICL sales were up ...